Daan Gene is thrilled to announce the launch of our new product---CYP2C19 Genotyping Diagnostic Kit (PCR-Fluorescence Probing).
The CYP2C19 Genotyping Diagnostic Kit is an in vitro diagnostic test used to detect and identify the polymorphisms of CYP2C19*2（c. 681G＞A）, CYP2C19*3（c. 636G＞A）and CYP2C19*17（c. -806C＞T）in human whole blood samples. This kit is a qualitative genotyping assay that can be used as an aid to clinicians in determining the strategy for the therapeutics that are metabolized by the CYP2C19 gene product.
There are at least ten different CYP2C19 alleles, which are represented by *1, *2, *3... etc. The combination of the alleles determines the overall level of CYP2C19 enzyme activity or phenotype. CYP2C19 is generally divided into ultrafast metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM) and poor metabolizer (PM) based on its activity. CYP2C19 metabolizes 5% of the prescription drugs in current clinical use. Some of the commonly used and largest selling therapeutics for heart disease, depression, and fungal treatments are all metabolized by CYP2C19, especially the antiplatelet treatment clopidogrel (Plavix). Understanding a patient’s CYP2C19 genotype can help doctors select the drugs and doses best suited for each person.